Table 1 Detailed patients’ characteristics.

From: Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience

 

Sex

Age (y)

WHO/ECOG

Disease duration (y)

DTC type

Extent of disease

Metastatic sites

Prior therapy

Long-term TKI response

1

f

47

1

16

oncocytic

metastatic

LN, bone, liver, lung

surgery, RIT, PRRT

PR

2

m

52

0

10

oncocytic

metastatic

LN, bone, lung

surgery, RIT, RTx

SD

3

f

70

0

16

follicular

metastatic

LN, bone, lung

surgery, RIT

PR

4

f

64

0

11

follicular

metastatic

LN, liver, lung

surgery, RIT

PD

5

m

57

0

13

follicular

metastatic

LN, bone, lung

surgery, RIT, RTx

PR

6

m

62

2

8

papillary

metastatic

lung

surgery, RIT, sorafenib

SD

7

m

69

1

13

papillary

metastatic

LN, bone, lung

surgery, RIT

PR

8

m

68

0

21

follicular

metastatic

LN, lung

surgery, RIT, RTx

PD

9

m

64

0

6

follicular

metastatic

LN, lung

surgery, RIT, RTx, sorafenib

PD

  1. DTC = differentiated thyroid cancer, ECOG = Eastern Cooperative Oncology Group, f = female, LN = lymph node, m = male, PD = progressive disease, PR = partial response, PRRT = peptide receptor radionuclide therapy, RIT = radioiodine therapy, RTx = external radiation therapy, SD = stable disease, TKI = tyrosine kinase inhibitor, WHO = World Health Organization.
Back to article page